Table 3.
Treatment related adverse events in the two groups
| Adverse events, n (%) | Any Grade | Grade 3 or 4 | |||||
|---|---|---|---|---|---|---|---|
| TACE + A group (n = 477) | TACE + AC group (n = 483) | p value | TACE + A group (n = 477) | TACE + AC group (n = 483) | p value | ||
| Adverse events related to TACE | |||||||
| Fever | 237 (49.7) | 227 (47.0) | 0.230 | 0 | 0 | – | |
| Pain | 199 (41.7) | 208 (43.1) | 0.516 | 12 (2.5) | 19 (3.9) | 0.108 | |
| Gastrointestinal reaction | 154 (32.3) | 164 (34.0) | 0.417 | 0 | 0 | – | |
| Nausea and vomiting | 142 (29.8) | 148 (30.6) | 0.622 | 2 (0.4) | 3 (0.6) | 0.535 | |
| Ascites | 51 (10.7) | 62 (12.8) | 0.156 | 5 (1.0) | 6 (1.2) | 0.640 | |
| Liver abscess | 8 (1.7) | 13 (2.7) | 0.165 | 4 (1.0) | 8 (2.1) | 0.114 | |
| Hepatic artery thinning in 2nd TACE | 101 (21.2) | 157 (32.5) | < 0.001 | 0 | 0 | – | |
| Hepatic artery spasm in 2nd TACE | 46 (9.6) | 63 (13.0) | 0.027 | 0 | 0 | – | |
| Adverse events related to apatinib and/or camrelizumab | |||||||
| Any adverse event | 386 (80.9) | 388 (80.3) | 0.672 | 127 (26.6) | 131 (27.1) | 0.715 | |
| Hypertension | 202 (42.3) | 197 (40.8) | 0.458 | 51 (10.7) | 44 (9.5) | 0.365 | |
| Hand-foot syndrome | 205 (43.0) | 186 (38.5) | 0.044 | 42 (8.8) | 37 (7.7) | 0.330 | |
| Fatigue | 178 (37.3) | 167 (34.6) | 0.200 | 0 | 0 | – | |
| Diarrhea | 95 (19.9) | 111 (23.0) | 0.109 | 5 (1.0) | 3 (0.6) | 0.226 | |
| RCCEP | 5 (1.0) | 103 (21.3) | < 0.001 | 0 | 0 | – | |
| Mouth ulcers | 85 (17.8) | 94 (19.5) | 0.347 | 0 | 0 | – | |
| Rash | 84 (17.6) | 79 (16.4) | 0.433 | 0 | 0 | – | |
| Proteinuria | 88 (18.4) | 76 (15.7) | 0.101 | 13 (2.7) | 11 (2.3) | 0.480 | |
| Abdominal pain | 7 (1.5) | 69 (14.3) | < 0.001 | 2 (0.4) | 3 (0.6) | 0.535 | |
| Hyperammonemia | 15 (3.1) | 66 (13.7) | < 0.001 | 0 | 12 (2.5) | – | |
| Decreased appetite | 73 (15.3) | 62 (12.8) | 0.104 | 0 | 0 | – | |
| Headache | 69 (14.5) | 57 (11.6) | 0.070 | 0 | 0 | – | |
| Hypothyroidism | 4 (0.8) | 49 (10.1) | < 0.001 | 0 | 0 | – | |
| Thrombocytopenia | 59 (12.4) | 48 (9.9) | 0.074 | 3 (0.6) | 2 (0.4) | 0.438 | |
| Gastrointestinal hemorrhage | 53 (11.1) | 49 (10.1) | 0.455 | 12 (2.5) | 11(2.3) | 0.659 | |
| Immune-related pneumonia | 0 | 10 (2.1) | – | 0 | 4 (0.8) | – | |
| Immune-related myocarditis | 0 | 6 (1.2) | – | 0 | 2 (0.4) | – | |
TACE transcatheter arterial chemoembolization, A apatinib, C camrelizumab, RCCEP reactive cutaneous capillary endothelial proliferation